Weekly Digest – August 2025 Weekly Digest – August 2025 25 August 2025: DATROWAY approved in China for patients with previously treated metastatic HR Positive, HER2 negative breast cancer DATROWAY (Datopotamab deruxtecan) has been approved in China for patients with […]
Weekly Digest – August 2025 Weekly Digest – August 2025 25 August 2025: ENHERTU approved in Japan as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer following at least one endocrine therapy ENHERTU […]
Weekly Digest – August 2025 Weekly Digest – August 2025 26 August 2025: Genmab receives FDA Breakthrough Therapy Designation for Rinatabart sesutecan (Rina-S) in advanced endometrial cancer (EC) The FDA granted Breakthrough Therapy Designation to Genmab’s rinatabart sesutecan (Rina-S) for […]
Weekly Digest – August 2025 Weekly Digest – August 2025 27 August 2025: HERTHENA-Breast04 Phase 3 trial of Patritumab deruxtecan initiated in patients with metastatic hormone receptor positive, HER2 negative breast cancer previously treated with endocrine therapy Daiichi Sankyo and […]
Weekly Digest – August 2025 Weekly Digest – August 2025 23 August 2025: Koas acquires antibody drug developer Novelty Nobility Koas, Korea’s top office furniture maker, announced a KRW 50 billion investment to acquire Novelty Nobility, making it a subsidiary […]
Weekly Digest – August 2025 Weekly Digest – August 2025 28 August 2025: Indena and TCG GreenChem join forces to advance next-generation ADC technologies Indena and TCG GreenChem formed a strategic partnership to accelerate payload–linker development for ADCs Indena contributes […]
